News Items

Cancer Research UK recently highlighted the Ivy Brain Tumor Center for its groundbreaking work in glioblastoma research. Led by Dr. Nader Sanai, whose personal connection to the disease drives his passion, the Ivy Center is at the forefront of developing innovative treatments for brain cancer. With a focus on overcoming challenges such as limited drug development and complex tumor biology, the Ivy Center is committed to advancing therapies that can improve the lives of patients with glioblastoma.

Dr. Shewetal Mehta, PhD, Deputy Director at the Ivy Brain Tumor Center, discusses cutting-edge brain cancer research with CancerNetwork®. She shares insights on early-phase clinical trials, including a phase 0/1 trial for BDTX-1535, an EGFR inhibitor for high-grade glioma, and the importance of biomarker testing in personalizing treatment. Dr. Mehta also explores the potential of new therapies like proteolysis targeting chimeras and antibody-drug conjugates. Explore more by watching her mini-episodes now.

Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, was featured on the WeTrials Podcast, where he discussed groundbreaking advancements in brain tumor research and clinical trials. In the episode, Dr. Sanai highlights the role of early-phase clinical trials in developing new treatments, including the promising potential of Niraparib, a drug moving from trials to global studies. He also explores how genomic data is revolutionizing personalized medicine for brain tumor patients, offering hope for better outcomes. Tune in to hear Dr. Sanai’s insights on the future of brain tumor care and the innovative work being done at the Ivy Brain Tumor Center. Watch now!

The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the expansion of the Gliofocus Study, activating two new sites in Europe and two additional locations in the United States. The newly activated sites include Groupe Hospitalier Pitié-Salpêtrière in Paris, France; Hospital Universitario 12 de Octubre in Madrid, Spain; The NeuroMedical Center Clinic in Baton Rouge, Louisiana; and UC San Diego Moores Cancer Center in La Jolla, California. The Gliofocus Study is an open-label, randomized Phase 3 trial (NCT06388733) that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma. 

The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the 19th Meeting of the European Association of Neuro-Oncology (EANO), which will take place in Glasgow, Scotland, October 17-20, 2024.

In a conversation with CancerNetwork®, Nader Sanai, MD discussed the current state of the glioblastoma field, highlighting ongoing research efforts to help improve outcomes among patients with this disease.

Dr. Yoshie Umemura joins CancerNetwork to discuss the power of multidisciplinary collaboration in enhancing brain cancer patient care and the importance of accelerating clinical trials like the Gliofocus trial to advance research. She also emphasizes the value of seeking mentorship and building connections within the brain cancer field as key to professional growth and impactful research. Watch her share these insights and more in her latest discussion!

Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, has been named the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. This prestigious honor recognizes Dr. Sanai's pioneering efforts and unwavering dedication to advancing new therapies for brain tumor patients, breaking new ground in the fight against this challenging disease.

Dr. Nader Sanai shares key insights on Cancer Network, exploring innovative strategies in early neuro-oncology that could offer new hope for glioblastoma treatment. He discusses the promising potential of combining niraparib with radiotherapy, as highlighted in a proof-of-concept study showing a possible survival benefit for patients with newly diagnosed glioblastoma. Don't miss his mini-episodes for valuable perspectives on these groundbreaking developments in brain cancer research.

Arizona Family recently featured the Ivy Brain Tumor Center and Dr. Nader Sanai, who highlighted the seriousness of glioblastoma (GBM). Lanette Veres, a brain tumor survivor diagnosed with a grade 3 glioma in 1998, shared her inspiring journey of resilience after losing her grandmother to GBM. Veres founded the Gray Matters Foundation in 2007 to support brain cancer patients and remains hopeful about new treatments, stating, “Hope never grows old.” Our Phase 3 Gliofocus Study testing the drug Niraparib, has shown promising results in early trials. Watch now!